DDrare: Database of Drug Development for Rare Diseases

Rc18 240mg (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
66	IgA nephropathy	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04625153 (ClinicalTrials.gov)	December 2020	6/11/2020	RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial	RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial	Multiple Sclerosis, Relapsing-Remitting	Biological: RC18 160mg;Biological: RC18 240mg	RemeGen	NULL	Not yet recruiting	18 Years	55 Years	All	18	Phase 2	NULL

66. IgA nephropathy [ 199 clinical trials, 214 drugs, (DrugBank: 57 drugs), 32 drug target genes, 128 drug target pathways]

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 199 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04291781 (ClinicalTrials.gov)	March 2020	27/2/2020	A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy	Phase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of IgA Nephropathy	IgA Nephropathy	Biological: RC18 160mg;Biological: RC18 240mg;Biological: placebo	RemeGen	NULL	Recruiting	18 Years	70 Years	All	30	Phase 2	China